Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis: A Meta-analysis With Reconstructed Individual Patient Data (P4-20.010)

Moaz Ezz-Alarab; Mohamed Ahmed Zanaty; Mohamed Ahmed Ali; Mark Messak; Moaz Nader; Abdelrahman Shata; Ismail A. Ibrahim

doi:10.1212/wnl.0000000000217245

June 9, 2026Neurology

Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis: A Meta-analysis With Reconstructed Individual Patient Data (P4-20.010)

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to assess the efficacy and safety of BTK inhibitors compared to placebo and teriflunomide in MS patients.
Conducted a meta-analysis with reconstructed individual patient data.
Compared outcomes of BTK inhibitors against placebo and teriflunomide.
Included multiple studies that evaluated BTK inhibitors in patients with Multiple Sclerosis.
BTK inhibitors showed superior efficacy compared to placebo (P<0.05).
Safety profiles of BTK inhibitors were comparable to teriflunomide.
Improved outcomes were noted in functional measures among BTK inhibitor users.

Implication

Meta-analysis compares efficacy and safety of BTK inhibitors in MS patients, indicating potential benefits over standard treatments.

Abstract

To compare the efficacy and safety of Bruton's tyrosine kinase (BTK) inhibitors against placebo and teriflunomide in patients with Multiple Sclerosis (MS).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ezz-Alarab et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf3b4faef96ed7f0561ae https://doi.org/10.1212/wnl.0000000000217245

View Full Paper

Ask AI

Bookmark

Share

Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis: A Meta-analysis With Reconstructed Individual Patient Data (P4-20.010)

Key Points

Implication

Abstract

Discussion

Cite This Study

Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis: A Meta-analysis With Reconstructed Individual Patient Data (P4-20.010)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading